1. A combination comprising:

(a) an MCL-1 inhibitor which is (2*R*)-2-{[(5*S*$_a$)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[1-(2,2,2-trifluoroethyl)-1*H*-pyrazol-5-yl]methoxy}phenyl)propanoic acid or (2*R*)-2-{[(5*S*$_a$)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid

or an addition salt[[s]] thereof with a pharmaceutically acceptable acid or base,

and (b) a taxane compound which is paclitaxel or docetaxel.

2. The combination according to claim 1, wherein the MCL-1 inhibitor is (2*R*)-2-{[(5*S*$_a$)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[1-(2,2,2-trifluoroethyl)-1*H*-pyrazol-5-yl]methoxy}phenyl)propanoic acid.

3. The combination according to claim 1, wherein the MCL-1 inhibitor is (2*R*)-2-{[(5*S*$_a$)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid.

4. The combination according to claim 3, wherein the (2*R*)-2-{[(5*S*$_a$)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid is present at a dosage from 25 mg to 1500 mg.

5. The combination according to claim 1, further comprising one or more excipients.

6. A pharmaceutical composition comprising the combination according to claim 1, in combination with one or more pharmaceutically acceptable excipients.

7. The pharmaceutical composition according to claim 6, which is packaged for

simultaneous, sequential or separate administration.

8. Use of a combination according to claim 1 in the manufacture of a medicament for treating cancer, comprising administration of an effective amount of the combination, alone or in combination with one or more pharmaceutically acceptable excipients.

9. The use according to claim 8, wherein the MCL-1 inhibitor and the taxane compound are administered in amounts which are jointly therapeutically effective for the treatment of cancer.

10. The use according to claim 8, wherein the MCL-1 inhibitor and the taxane compound are administered in amounts which are synergistically effective for the treatment of cancer.

11. The use according to claim 8, wherein the MCL-1 inhibitor and the taxane compound are administered in synergistically effective amounts which enable a reduction of the dose required for each compound in the treatment of cancer, whilst providing an efficacious cancer treatment, with eventually a reduction in side effects.

12. The use according to claim 8, wherein the cancer is breast cancer.

13. The use according to claim 8, wherein the cancer is lung cancer.

14. The use according to claim 8, wherein the MCL-1 inhibitor is administered once a week.

15. The use according to claim 8, wherein the MCL-1 inhibitor and the taxane compound are administered intravenously.

16. The use according to claim 8, wherein the MCL-1 inhibitor is administered orally and the taxane compound is administered intravenously.